Novavax To Initiate COVID-19 Phase 2 Influenza Combination, Stand Along Vaccine Trials

Novavax, Inc. (NVAX) Friday announced the start of the phase 2 trial for COVID-19 influenza combination and stand-alone influenza vaccine candidates.

The dose-confirming trial will be done in adults of 50 to 80 years to evaluate safety and effectiveness. The initial trial is scheduled for mid-year 2023.

The company said the Phase 2 dose-confirmation trial to be done in two parts will enroll approximately 2,300 participants across multiple sites in Australia and New Zealand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Food and Drug Administration has cleared cultivated chicken developed by GOOD Meat Inc., the cultivated meat division of alternative foods startup Eat Just Inc. This is FDA's second pre-market consultation for a human food made from cultured animal cells after UPSIDE Foods. GOOD Meat is now required to meet Federal requirements including approvals from the US Department of Agriculture. A group of 23 U.S. states attorneys general have asked South Korean car manufacturers Hyundai Motor and Kia Corp. to take action more quickly to solve problems with millions of U.S. vehicles facing theft. The issue is related to the companies' failure to equip vehicles with anti-theft immobilizers, which has been a standard equipment on vehicles sold by other major manufacture El Monte, California-based Mutual Trading Co., Inc. is recalling certain Kagome Sauces citing undeclared soy, a known allergen, the U.S. Food and Drug Administration said. The recall involves 60 fl oz of Kagome Worcester Sauce, 10 fl oz of Kagome Chuno sauce, and 8g of Kagome Take out Tonkatsu Sauce.
Follow RTT